III期-话题@MedSci

#III期#

681篇内容 | 2796人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594647, encodeId=aa64159464e96, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, objectType=article, longId=180261, objectId=29ed18026114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ed18026114, replyNumber=0, likeNumber=51, createdTime=2019-10-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ed18026114, moduleTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ed18026114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594646, encodeId=6d5c159464605, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=15, createdTime=2019-09-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗, objectType=article, longId=180140, objectId=317118014061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317118014061, replyNumber=0, likeNumber=0, createdTime=2019-09-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317118014061, moduleTitle=国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317118014061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594644, encodeId=c45215946442c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=60, createdTime=2019-09-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594643, encodeId=3835159464370, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, objectType=article, longId=179522, objectId=8c931e952273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c931e952273, replyNumber=0, likeNumber=0, createdTime=2019-09-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c931e952273, moduleTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c931e952273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594642, encodeId=d9c715946425a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=abexinostat治疗肾癌的III期研究：首位中国患者已经入组, objectType=article, longId=179479, objectId=787e1e9479e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787e1e9479e7, replyNumber=0, likeNumber=50, createdTime=2019-09-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787e1e9479e7, moduleTitle=abexinostat治疗肾癌的III期研究：首位中国患者已经入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787e1e9479e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594641, encodeId=f3dd159464182, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, objectType=article, longId=179450, objectId=b45b1e9450d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45b1e9450d9, replyNumber=0, likeNumber=57, createdTime=2019-09-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45b1e9450d9, moduleTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45b1e9450d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594640, encodeId=255b15946405a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=63, createdTime=2019-09-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594639, encodeId=f729159463916, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, objectType=article, longId=178809, objectId=55521e880970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55521e880970, replyNumber=0, likeNumber=62, createdTime=2019-09-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55521e880970, moduleTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55521e880970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594638, encodeId=a7ff1594638c8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, objectType=article, longId=178786, objectId=cbc51e8786dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc51e8786dd, replyNumber=0, likeNumber=16, createdTime=2019-09-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc51e8786dd, moduleTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc51e8786dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594637, encodeId=fd40159463e58, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, objectType=article, longId=178689, objectId=11b21e8689cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11b21e8689cf, replyNumber=0, likeNumber=76, createdTime=2019-09-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11b21e8689cf, moduleTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11b21e8689cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594636, encodeId=d33715946363f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, objectType=article, longId=178688, objectId=6d301e8688c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d301e8688c1, replyNumber=0, likeNumber=61, createdTime=2019-09-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d301e8688c1, moduleTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d301e8688c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594635, encodeId=9805159463574, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=0, createdTime=2019-09-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594634, encodeId=0e47159463420, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, objectType=article, longId=178240, objectId=d4021e824003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4021e824003, replyNumber=0, likeNumber=19, createdTime=2019-08-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4021e824003, moduleTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4021e824003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594633, encodeId=15cc1594633ed, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=51, createdTime=2019-08-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594632, encodeId=90a515946323b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标, objectType=article, longId=177803, objectId=fbaf1e78035c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbaf1e78035c, replyNumber=0, likeNumber=70, createdTime=2019-08-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbaf1e78035c, moduleTitle=Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbaf1e78035c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594631, encodeId=bb7315946313d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=99, createdTime=2019-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594630, encodeId=033c15946303a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=70, createdTime=2019-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594629, encodeId=de0215946299d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, objectType=article, longId=177574, objectId=06bb1e7574a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bb1e7574a5, replyNumber=0, likeNumber=76, createdTime=2019-08-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bb1e7574a5, moduleTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06bb1e7574a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594628, encodeId=5438159462824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=0, createdTime=2019-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉

2019-10-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2019-09-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

国内III期肺癌规范化诊疗示范中心正式成立，精准助力III期肺癌规范化诊疗

2019-09-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-09-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果

2019-09-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

abexinostat治疗肾癌的III期研究：首位中国患者已经入组

2019-09-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点

2019-09-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点

2019-09-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究

2019-09-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

2019-09-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏Xofluza作为预防性流感药物III期临床安全有效

2019-09-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2019-09-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标

2019-08-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2019-08-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标

2019-08-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功

2019-08-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论

2019-08-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2019-08-12

科室
- - 订阅+
  - 更多科室
工具
服务